Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Contact 844-434-4210
Participate-In-This-Study1@its.jnj.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Back

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Recruiting

Open to: ALL

Age: 18.0 - N/A

London Hull London Leeds Northwood Birmingham London

Medical Conditions

Colorectal Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2024 Dec 2027

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : Amivantamab will be administered.

Intervention Arm Group : Arm A: Amivantamab + FOLFIRI;

Intervention Type : BIOLOGICAL
Intervention Description : Cetuximab will be administered.

Intervention Arm Group : Arm B: Cetuximab or Bevacizumab + FOLFIRI;

Intervention Type : BIOLOGICAL
Intervention Description : Bevacizumab will be administered.

Intervention Arm Group : Arm B: Cetuximab or Bevacizumab + FOLFIRI;

Intervention Type : DRUG
Intervention Description : 5-fluorouracil will be administered as chemotherapy regimen.

Intervention Arm Group : Arm A: Amivantamab + FOLFIRI;Arm B: Cetuximab or Bevacizumab + FOLFIRI;

Intervention Type : DRUG
Intervention Description : Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

Intervention Arm Group : Arm A: Amivantamab + FOLFIRI;Arm B: Cetuximab or Bevacizumab + FOLFIRI;

Intervention Type : DRUG
Intervention Description : Irinotecan will be administered as chemotherapy regimen.

Intervention Arm Group : Arm A: Amivantamab + FOLFIRI;Arm B: Cetuximab or Bevacizumab + FOLFIRI;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College Hospital
    London
    NW1 2BU
  • Castle Hill Hospital
    Hull
    HU16 5JQ
  • Royal Marsden Hospital
    London
    SW3 6JJ
  • St James University Hospital
    Leeds
    LS9 7TF
  • Mount Vernon Cancer Centre
    Northwood
    HA6 2RN
  • Birmingham Heartlands Hospital
    Birmingham
    B9 5ST
  • St Bartholomew's Hospital
    London
    EC1A 7BE

Study Contact 844-434-4210
Participate-In-This-Study1@its.jnj.com



The study is sponsored by Janssen Research & Development, LLC



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06750094
Last updated 04 June 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top